The impact of opioid on the United States and its communities is a constantly growing burden and is challenging for patients and the health care community. Pharmacists are important members of the treatment team, particularly when it comes to addressing the opioid crisis. Awareness, patient communication, and education as well as bidirectional communication with prescribers are all imperative to doing what is best for the patient. This includes identifying and using appropriate screening tools and reviewing available options for naloxone and medicated assisted treatment (MAT) for individuals with opioid use disorder.
This CMEOCast podcast episode features expert faculty focused on the role of the pharmacist in communicating with patients about their prescribed opioids and in recommending and/or dispensing naloxone to individuals prescribed opioids who may be at risk for overdose, and available options for medicated assisted treatment (MAT).
At the end of this CME/CE activity, participants should be able to:
Supported by an educational grant from Johnson & Johnson.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process.
John G. Gums, PharmD, FCCP, has no disclosures to report.
Carol Anne A. Motycka, PharmD, BCACP, has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff; no disclosures to report:
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.